Plain-English translation of NCT07013591 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether nicotinamide mononucleotide (NMN), a naturally occurring compound, can help protect your heart and kidneys when you undergo coronary artery bypass surgery. The medication works by boosting energy production in your heart cells. Researchers want to see if taking it before and after surgery reduces damage to your heart and kidneys.
Heart bypass surgery can sometimes cause injury to the heart and kidneys during the procedure. This trial is exploring whether this supplement, by helping cells produce energy more efficiently, could reduce that damage and lead to better recovery.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the medication or a placebo (inactive pill). One group takes the medication for 7 days before surgery, one group takes it for 2 days before surgery, and one group receives placebo. All groups take their assigned treatment on the day of surgery and for 4 days afterward. You'll take the medication by mouth twice daily, and the study team will monitor your heart and kidney health through standard surgical follow-up care.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Brigham and Women's Hospital
Collaborators
National Institute on Aging (NIA)
Enrollment target
~90 participants
Started
June 2026
Primary completion
October 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Shalender Bhasin, MB,BS
Brigham and Women's Hosptial
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.